Compare Amphastar Pharmaceuticals Inc (AMPH) vs Domino's Pizza, Inc. (DPZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Domino's Pizza, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Domino's Pizza, Inc. trades at $300.26 (market cap $9.96B). The key difference: Domino's Pizza, Inc. is far larger — about 12.1× Amphastar Pharmaceuticals Inc's market cap, and Domino's Pizza, Inc. pays a 2.66% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | DPZ | |
|---|---|---|
Market Cap | $826.08M | $9.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $485.53 |
52-Week Low | $16.87 | $282.89 |
Enterprise Value | $1.22B | $14.86B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Domino's Pizza (DPZ) trades at $299.46, down 0.47% on the day, near its 52-week low. The stock shows a bearish technical signal with support at $297 and resistance at $304. Fundamentally, revenue grew to $4.94B in 2025 with a net income margin of 11.89%, though recent quarters have seen earnings misses. The company maintains strong profitability but faces headwinds from slowing US sales growth and a CEO transition announced in June 2026.
The outlook is mixed: analyst consensus is bullish with a $380.31 price target, but near-term risks include competitive pressures and macroeconomic challenges. Long-term investors may find value at current levels given the company's market dominance and digital capabilities, though execution under new leadership and sales recovery are critical for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →
